Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaCardia's Dittrich and Woods join Sorbent

This article was originally published in Scrip

Executive Summary

Privately-held biopharmaceutical company Sorbent Therapeutics has appointed Dr Howard Dittrich its first chief medical officer and Randall Woods chair of the board of directors. Dr Dittrich has over 20 years' experience having led clinical research and regulatory affairs at biotech companies such as NovaCardia, Alliance Pharmaceuticals and Molecular Biosystems. He was most recently CMO at Sequel Pharmaceuticals, a spin-out from the acquisition of NovaCardia (the company he co-founded) by Merck & Co. Mr Woods, a serial entrepreneur, has over 39 years' experience in the industry and previously served as president and CEO of Sequel Pharmaceuticals and NovaCardia.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017101

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel